Dallas and Fort Worth, Texas–(business wire) — Satori Capital, a multi-strategy investment firm founded on the principles of conscious capitalism, today announced a new investment focused on transformative companies developing innovative solutions for mental health. announced the launch of the business.
Satori Neuro is for companies developing breakthrough therapies and disruptive business models to address the world’s most important mental health challenges. Supporting this kind of innovation aligns directly with his Satori purpose to create, fund and inspire businesses that improve humanity.
Satori Alpha Chief Investment Officer and Managing Partner James Haddaway said: “We strongly believe in the tremendous potential of these innovative solutions, so if we can find the ideal Chief Investment Officer to lead a focused strategy, we will do it ourselves. I decided to explore.”
In their search for their ideal leader, Satori’s principals focused on the key qualities they believed were necessary to succeed in this cutting-edge field. This Chief Investment Officer requires not only a strong scientific and managerial background, but also deep connections with entrepreneurs and business leaders, and the ability to serve as a trusted value-adding partner to strategic portfolio companies. . Satori was also looking for a proven leader who was strongly aligned with Satori’s purpose and core values.
Extensive research led us to just such a leader, Dr. Amy Kruse. Dr. Kruse has over 20 years of experience in science, technology and innovation, with a particular focus on neuroengineering and human performance. She is a former General Manager of her partner at Prime Movers Lab, her venture capital firm that invests in early-stage science-driven startups developing solutions to some of the world’s most pressing problems. Previously, she served as Chief Scientific Officer for Applied Neuroscience research company Optios, and has experience as Chief Technology Officer for Cubic Global Defense and as her program manager for the Defense Advanced Research Projects Agency (DARPA). Dr. Kruse holds a BS and Ph.D. in Cellular and Structural Biology. She received her PhD in Neuroscience from the University of Illinois at Urbana-Champaign.
“Amy’s experience and subject matter expertise, as well as her impressive professional background, put her in an ideal position to lead this innovative neuroscience and mental health-related strategy,” said Satori, co-founder. Managing Partner Randy Eisenman said. “Amy’s unique expertise, experience and relationships, along with Principal’s operational experience in building and managing successful companies, provide a distinct advantage in recognizing the most promising and innovative businesses in this space. I believe.”
Satori’s recognition of Dr. Kruse’s excellence in her field is based on her previous recognition, including Dr. Jonathan Spawn, CEO of Gilgamesh Pharmaceuticals, a clinical-stage biotechnology company developing therapeutic-based new drugs. It’s also reflected in the entrepreneurs and business leaders we’ve worked with in our roles. A psychedelic drug promises to revolutionize the treatment of mental illness.
“Amy is an ideal collaborator, both as an investor and as a thought partner,” Spawn said. “She has played a key role in our success at Gilgamesh Pharmaceuticals. She brings that energy to the work of venture investing through her career.She is scientifically astute, hands-on, and incredibly well-connected, and any company is lucky to have her involved.”
Under Dr. Kruse’s direction, Satori Neuro will explore opportunities to address the greatest mental health, brain health, and wellness challenges and opportunities. Associated innovative treatments include a wide range of therapeutic approaches, from psychedelic medicine and transcranial magnetic stimulation to virtual/augmented reality protocols and non-invasive electroencephalographic devices, all of which are associated with treatment-resistant depression, post-traumatic stress. It is designed to provide solutions to challenges such as disability, addiction and substance abuse, neurological disorders, and more.
“This is a thrilling time for neuroscience and brain health,” said Dr. Kruse. “We have learned more about the human brain in the last five years than we have learned in the last 50 years. That knowledge has the potential to completely change the way we approach mental health challenges.” It is rapidly changing to real-world applications that hold secrets that we have struggled with throughout human history.I see these innovations as the future of human prosperity, breakthrough therapies and new business models. We are pleased to partner with a purpose-driven company like Satori to help companies develop
About Satori Capital
Satori Capital is a Texas-based multi-strategic investment firm founded on the principles of conscious capitalism. The purpose of this company is to create, fund and inspire businesses that improve humanity. Through majority and minority investments, Satori’s Private Equity business partners work with his $5M to his $50M EBITDA company’s leadership team to operate with a long-term view and focus on mission and purpose. We are committed to and create value for all our stakeholders. Satori Alpha, Satori’s alternative investment platform, creates and manages customized portfolios designed to meet the unique objectives of sophisticated individual investors, family offices, and institutions. Through the Satori XL Partnership Program, Satori will partner with managers who are highly skilled in generating sustainable alpha and who will benefit from Satori’s experience, relationships and resources, all of which will contribute to the growth of a thriving and lasting business. Supports construction. Satori Environmental invests in securities impacted by the shift of the global energy sector towards more renewable energy sources. For more information, please visit www.satoricapital.com.